Summit Therapeutics Inc. Cash Flows From Used In Operations Before Changes In Working Capital
Summit Therapeutics Inc. (SMMT) reported Cash Flows From Used In Operations Before Changes In Working Capital of -GBP 8.10 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Notes
ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital · last filed 2020-06-02
- Summit Therapeutics Inc. cash flows from used in operations before changes in working capital for the quarter ending 2020-03-31 was -8.10M GBP.
- Summit Therapeutics Inc. cash flows from used in operations before changes in working capital for the quarter ending 2019-10-31 was -5.92M GBP.
- Summit Therapeutics Inc. cash flows from used in operations before changes in working capital for the quarter ending 2019-07-31 was -6.77M GBP, a 123.66% decline year-over-year.
- Summit Therapeutics Inc. cash flows from used in operations before changes in working capital for the quarter ending 2019-04-30 was -4.47M GBP.
| Period end | Cash Flows From Used In Operations Before Changes In Working Capital 3 month | Cash Flows From Used In Operations Before Changes In Working Capital 3 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 6 month | Cash Flows From Used In Operations Before Changes In Working Capital 6 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 9 month | Cash Flows From Used In Operations Before Changes In Working Capital 9 month as first filed | Cash Flows From Used In Operations Before Changes In Working Capital 11 month | Cash Flows From Used In Operations Before Changes In Working Capital 12 month | Cash Flows From Used In Operations Before Changes In Working Capital 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -8.10M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | -22.83M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | -5.92M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | -12.70M GBP derived: sum of 2 quarters · filed 2019-12-17 | -17.17M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | -6.77M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | -11.25M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | -4.47M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | -4.78M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | -4.29M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -9.69M GBP derived: sum of 2 quarters · filed 2020-04-30 | 18.94M GBP derived: sum of 3 quarters · filed 2020-04-30 | 12.74M GBP 20-F · filed 2020-04-30 | 12.07M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | -5.40M GBP derived: 6-K 9 month − 6-K 6 month · filed 2019-12-17 | 23.24M GBP derived: sum of 2 quarters · filed 2019-12-17 | 17.04M GBP 6-K · filed 2019-12-17 | 16.78M GBP 6-K · filed 2018-12-11 | 8.21M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-07-31 | 28.63M GBP derived: 6-K 6 month − 6-K 3 month · filed 2019-10-11 | 22.43M GBP 6-K · filed 2019-10-11 | 22.27M GBP 6-K · filed 2018-09-20 | 13.60M GBP derived: sum of 3 quarters · filed 2020-04-30 | 7.91M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-04-30 | -6.20M GBP 6-K · filed 2019-06-12 | -6.29M GBP 6-K · filed 2018-06-05 | -15.03M GBP derived: sum of 2 quarters · filed 2020-04-30 | -20.72M GBP derived: sum of 3 quarters · filed 2020-04-30 | -24.06M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | -8.83M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -14.52M GBP derived: sum of 2 quarters · filed 2020-04-30 | -17.86M GBP derived: sum of 3 quarters · filed 2020-04-30 | -22.79M GBP 20-F · filed 2020-04-30 | -9.96M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | -5.69M GBP derived: 6-K 9 month − 6-K 6 month · filed 2018-12-11 | -9.03M GBP derived: sum of 2 quarters · filed 2018-12-11 | -13.96M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | -3.34M GBP derived: 6-K 6 month − 6-K 3 month · filed 2018-09-20 | -8.27M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | -4.93M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | -22.70M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | -19.32M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |